Tvardi Therapeutics, Inc.
NASDAQ: TVRD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Imran Alibhai
- Employees
- 12
- Headquarters
- Sugar Land, United States
- IPO year
- 2014
- Market cap
- $22.0M
- Website
- https://tvarditherapeutics.com
Loading TVRD…
Loading profile data…Frequently asked questions about TVRD
What does Tvardi Therapeutics, Inc. (TVRD) do?
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidate...
Where does TVRD trade?
Tvardi Therapeutics, Inc. (TVRD) trades on the NASDAQ.
What sector is TVRD in?
Tvardi Therapeutics, Inc. (TVRD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Tvardi Therapeutics, Inc.?
Imran Alibhai is the chief executive officer of Tvardi Therapeutics, Inc. (TVRD).
Where is Tvardi Therapeutics, Inc. headquartered?
Tvardi Therapeutics, Inc. is headquartered in United States.
Does TVRD pay a dividend?
Tvardi Therapeutics, Inc. (TVRD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TVRD go public?
Tvardi Therapeutics, Inc. (TVRD) completed its initial public offering in 2014.